Researchers plan to start a clinical trial for an additional dose of a coronavirus vaccine candidate co-developed by China’s CanSino Biologics and a military-backed research unit, according to a clinical trial registry.A single dose of the vaccine candidate Ad5-nCoV, one of a handful that China is pursuing, has final-stage trials lined up in Pakistan and Russia. The candidate has been approved for use in the Chinese military.Scientists outside the company have expressed concern that the…
Source link